{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T06:20:12Z","timestamp":1783146012134,"version":"3.54.6"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s12072-026-11062-y","type":"journal-article","created":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T14:55:42Z","timestamp":1773759342000},"page":"559-574","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical and metabolic benefits of efruxifermin in MASH: a GRADE-assessed meta-analysis of randomized trials with trial sequential analysis"],"prefix":"10.1007","volume":"20","author":[{"given":"Islam","family":"Rajab","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2718-8627","authenticated-orcid":false,"given":"Ahmed","family":"Emara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed S.","family":"Elgendy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ameer","family":"Awashra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed R.","family":"Ezz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eman Ayman","family":"Nada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Furqan A.","family":"Bhullar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yana","family":"Cavanagh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walid","family":"Baddoura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,17]]},"reference":[{"key":"11062_CR1","doi-asserted-by":"publisher","first-page":"goae069","DOI":"10.1093\/gastro\/goae069","volume":"12","author":"R Manikat","year":"2024","unstructured":"Manikat R, Ahmed A, Kim D. Current epidemiology of chronic liver disease. Gastroenterol Rep. 2024;12:goae069","journal-title":"Gastroenterol Rep"},{"key":"11062_CR2","doi-asserted-by":"publisher","DOI":"10.1002\/ccd.70169","author":"A Shubietah","year":"2025","unstructured":"Shubietah A, Awashra A, Milhem F, AbuBaha M, Tobeh M, Nazir A, et al. Increasing acute coronary syndrome mortality in cirrhosis after a period of decline: a national analysis of temporal and demographic disparities. Catheter Cardiovasc Interv. 2025. https:\/\/doi.org\/10.1002\/ccd.70169","journal-title":"Catheter Cardiovasc Interv"},{"key":"11062_CR3","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1097\/HEP.0000000000001254","volume":"82","author":"M Souza","year":"2025","unstructured":"Souza M, Al-Sharif L, Antunes VLJ, Huang DQ, Loomba R. Comparison of pharmacological therapies in metabolic dysfunction-associated steatohepatitis for fibrosis regression and MASH resolution: systematic review and network meta-analysis. Hepatology. 2025;82:10\u20131097","journal-title":"Hepatology"},{"key":"11062_CR4","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.cmet.2019.01.004","volume":"29","author":"SA Kliewer","year":"2019","unstructured":"Kliewer SA, Mangelsdorf DJ. A dozen years of discovery: insights into the physiology and pharmacology of FGF21. Cell Metab. 2019;29:246\u2013253. https:\/\/doi.org\/10.1016\/j.cmet.2019.01.004","journal-title":"Cell Metab"},{"key":"11062_CR5","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/nrd2792","volume":"8","author":"A Beenken","year":"2009","unstructured":"Beenken A, Mohammadi M. The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov. 2009;8:235\u2013253","journal-title":"Nat Rev Drug Discov"},{"key":"11062_CR6","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1172\/JCI23606","volume":"115","author":"A Kharitonenkov","year":"2005","unstructured":"Kharitonenkov A, Shiyanova TL, Koester A, Ford AM, Micanovic R, Galbreath EJ, et al. FGF-21 as a novel metabolic regulator. J Clin Invest. 2005;115:1627\u20131635","journal-title":"J Clin Invest"},{"key":"11062_CR7","doi-asserted-by":"publisher","first-page":"66","DOI":"10.11152\/mu-3309","volume":"25","author":"H Tian","year":"2023","unstructured":"Tian H, Zhang T, Zhou Y, Rastogi S, Choudhury R, Iqbal J. Role of emergency chest ultrasound in traumatic pneumothorax. An updated meta-analysis. Med Ultrason. 2023;25:66\u201371","journal-title":"Med Ultrason"},{"key":"11062_CR8","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1210\/en.2016-1917","volume":"158","author":"S Stanislaus","year":"2017","unstructured":"Stanislaus S, Hecht R, Yie J, Hager T, Hall M, Spahr C, et al. A novel Fc-FGF21 with improved resistance to proteolysis, increased affinity toward \u03b2-Klotho, and enhanced efficacy in mice and cynomolgus monkeys. Endocrinology. 2017;158:1314\u20131327. https:\/\/doi.org\/10.1210\/en.2016-1917","journal-title":"Endocrinology"},{"key":"11062_CR9","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/S2468-1253(23)00272-8","volume":"8","author":"SA Harrison","year":"2023","unstructured":"Harrison SA, Frias JP, Neff G, Abrams GA, Lucas KJ, Sanchez W, et al. Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Gastroenterol Hepatol. 2023;8:1080\u20131093","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"11062_CR10","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2502242","author":"M Noureddin","year":"2025","unstructured":"Noureddin M, Rinella ME, Chalasani NP, Neff GW, Lucas KJ, Rodriguez ME, et al. Efruxifermin in compensated liver cirrhosis caused by MASH. N Engl J Med. 2025. https:\/\/doi.org\/10.1056\/nejmoa2502242","journal-title":"N Engl J Med"},{"key":"11062_CR11","unstructured":"Higgins J, Thomas J, Chandler J, Cumpston M, Li T, Page M. Cochrane handbook for systematic reviews of interventions version 6.5 [Internet]. 2024. Available from: http:\/\/www.training.cochrane.org\/handbook"},{"key":"11062_CR12","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13643-021-01626-4","volume":"10","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst Rev. 2021;10:89","journal-title":"Syst Rev"},{"key":"11062_CR13","doi-asserted-by":"crossref","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 2019;l4898\u2013l4898.","DOI":"10.1136\/bmj.l4898"},{"key":"11062_CR14","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629\u2013634","journal-title":"BMJ"},{"key":"11062_CR15","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924\u2013926","journal-title":"BMJ"},{"key":"11062_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12874-017-0315-7","volume":"17","author":"J Wetterslev","year":"2017","unstructured":"Wetterslev J, Jakobsen JC, Gluud C. Trial sequential analysis in systematic reviews with meta-analysis. BMC Med Res Methodol. 2017;17:1\u201318","journal-title":"BMC Med Res Methodol"},{"key":"11062_CR17","doi-asserted-by":"publisher","first-page":"100563","DOI":"10.1016\/j.jhepr.2022.100563","volume":"5","author":"SA Harrison","year":"2023","unstructured":"Harrison SA, Ruane PJ, Freilich B, Neff G, Patil R, Behling C, et al. A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis. JHEP Rep. 2023;5:100563","journal-title":"JHEP Rep"},{"key":"11062_CR18","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1038\/s41591-021-01425-3","volume":"27","author":"SA Harrison","year":"2021","unstructured":"Harrison SA, Ruane PJ, Freilich BL, Neff G, Patil R, Behling CA, et al. Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial. Nat Med. 2021;27:1262\u20131271","journal-title":"Nat Med"},{"key":"11062_CR19","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","volume":"77","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, Abdelmalek MF, Caldwell S, Barb D, et al. AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77:1797\u20131835","journal-title":"Hepatology"},{"key":"11062_CR20","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.cgh.2024.02.022","volume":"23","author":"SA Harrison","year":"2025","unstructured":"Harrison SA, Frias JP, Lucas KJ, Reiss G, Neff G, Bollepalli S, et al. Safety and efficacy of efruxifermin in combination with a GLP-1 receptor agonist in patients with NASH\/MASH and type 2 diabetes in a randomized phase 2 study. Clin Gastroenterol Hepatol. 2025;23:103\u2013113","journal-title":"Clin Gastroenterol Hepatol"},{"key":"11062_CR21","doi-asserted-by":"publisher","first-page":"e70075","DOI":"10.1002\/edm2.70075","volume":"8","author":"A Hussein","year":"2025","unstructured":"Hussein A, Awashra A, Rajab I, Bdair M, Hamdan D, Nouri A, et al. Comparative effectiveness of bariatric surgery versus GLP-1 receptor agonists in reducing the risk of new-onset of NASH: a retrospective multinational cohort study from North America and Europe. Endocrinol Diabetes Metab. 2025;8:e70075","journal-title":"Endocrinol Diabetes Metab"},{"key":"11062_CR22","volume":"5","author":"S Dinerman","year":"2025","unstructured":"Dinerman S, Shu Y. Therapeutic strategies for MASH: an update on drug candidates under investigation in late-phase clinical trials. Int J Transl Med. 2025;5: 7","journal-title":"Int J Transl Med"},{"key":"11062_CR23","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1097\/HEP.0000000000000670","volume":"79","author":"F Kanwal","year":"2024","unstructured":"Kanwal F, Neuschwander-Tetri BA, Loomba R, Rinella ME. Metabolic dysfunction-associated steatotic liver disease: update and impact of new nomenclature on the American association for the study of liver diseases practice guidance on nonalcoholic fatty liver disease. Hepatology. 2024;79:1212\u20131219","journal-title":"Hepatology"},{"key":"11062_CR24","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/j.jhep.2024.04.034","volume":"81","author":"SA Harrison","year":"2024","unstructured":"Harrison SA, Rolph T, Knott M, Dubourg J. FGF21 agonists: an emerging therapeutic for metabolic dysfunction-associated steatohepatitis and beyond. J Hepatol. 2024;81:562\u2013576","journal-title":"J Hepatol"},{"key":"11062_CR25","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.3390\/ijms24021703","volume":"24","author":"R Nevola","year":"2023","unstructured":"Nevola R, Epifani R, Imbriani S, Tortorella G, Aprea C, Galiero R, et al. GLP-1 receptor agonists in non-alcoholic fatty liver disease: current evidence and future perspectives. Int J Mol Sci. 2023;24:1703","journal-title":"Int J Mol Sci"},{"key":"11062_CR26","first-page":"51","volume":"81","author":"F de Dolovitsch Oliveira","year":"2025","unstructured":"de Dolovitsch Oliveira F, Khalil SM, Sato EDBdeS, de Souza MHG, Meine GC. Efficacy and safety of fibroblast growth factor 21 analogues for metabolic dysfunction-associated steatohepatitis: a systematic review and meta-analysis. Ann Nutr Metab. 2025;81:51\u201360","journal-title":"Ann Nutr Metab"},{"key":"11062_CR27","doi-asserted-by":"publisher","first-page":"9943228","DOI":"10.1155\/ije\/9943228","volume":"2025","author":"Z Nie","year":"2025","unstructured":"Nie Z, Xu J, Liu Y, Cao Q, Qiu X, Su Y, et al. Effects and safety of FGF21 analogs on glycemic parameters, lipid profiles, and adiponectin in overweight and obese adults: a meta\u2010analysis of randomized controlled trials. Int J Endocrinol. 2025;2025:9943228","journal-title":"Int J Endocrinol"},{"key":"11062_CR28","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/S0140-6736(25)01073-6","volume":"406","author":"M Noureddin","year":"2025","unstructured":"Noureddin M, Frias JP, Neff GW, Lucas KJ, Behling C, Bedossa P, et al. Safety and efficacy of once-weekly efruxifermin versus placebo in metabolic dysfunction-associated steatohepatitis (HARMONY): 96-week results from a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial. Lancet. 2025;406:719\u2013730","journal-title":"Lancet"},{"key":"11062_CR29","doi-asserted-by":"publisher","first-page":"1594091","DOI":"10.3389\/fphar.2025.1594091","volume":"16","author":"S Li","year":"2025","unstructured":"Li S, Zou W, Zhou Y, Li W, Liao W, Li T, et al. A systematic review and meta-analysis of efruxifermin\u2019s efficacy in improving liver fibrosis in patients with NASH\/MASH. Front Pharmacol. 2025;16:1594091","journal-title":"Front Pharmacol"},{"key":"11062_CR30","doi-asserted-by":"publisher","DOI":"10.1097\/CRD.0000000000000932","author":"A Awashra","year":"2025","unstructured":"Awashra A, Nouri A, Hamdan A, Said H, Rajab I, Hussein A, et al. Metabolic dysfunction-associated steatotic liver disease as a cardiovascular risk factor: focus on atrial fibrillation. Cardiol Rev. 2025. https:\/\/doi.org\/10.1097\/CRD.0000000000000932","journal-title":"Cardiol Rev"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-026-11062-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12072-026-11062-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-026-11062-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T05:57:50Z","timestamp":1783144670000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12072-026-11062-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,17]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["11062"],"URL":"https:\/\/doi.org\/10.1007\/s12072-026-11062-y","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,17]]},"assertion":[{"value":"14 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no competing interests to declare that are relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}